Health News Releases

  • Today August 28
December 24, 2020 10:55
Health Professionals Petition CDC for Guidance: Americans Use Nasal Sprays to Combat COVID-19 Pandemic; Doctors Use in Treating Patients
Today, a consortium of 15 doctors, nurses and other public health professionals petitioned the Centers for Disease Control to issue Guidance calling on: Americans to use nasal sprays to combat the COV
December 23, 2020 16:00
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponat
December 23, 2020 13:45
Coagulo Medical Technologies Announces $6.5 Million in Financing to Accelerate Delivery of Disruptive Coagulation Diagnostics Platform
Coagulo Medical Technologies, an MIT-born startup that has developed the world’s first precision-medicine platform for comprehensive and targeted blood clotting management, today announced it has rais
December 22, 2020 11:00
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of
December 22, 2020 10:26
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc. today announced topline data from the ACCOLADE clinical study, the largest, randomized, blinded, placebo-c
December 21, 2020 17:05
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold i
December 21, 2020 11:30
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investiga
December 17, 2020 10:55
Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding
On November 20th, S-Alpha Therapeutics (“S-Alpha” Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Vent
December 15, 2020 15:15
DeltaTrak’s New Vaccine Supply Chain Solutions Meet All Three Temperature Management Profiles Required for Storage, Handling and Transport of COVID-19 Vaccines
DeltaTrak® announces customized vaccine temperature monitoring solutions compatible with the three temperature profiles required for transport, storage and handling of COVID-19 vaccines. This includes
December 15, 2020 11:25
Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress Postoperative Hyperoxia in Patients Undergoing Breast Surgery
Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Kumagai and colleagues at Iwate Medical University Hospital in Yahaba-cho, Jap
December 11, 2020 15:45
New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion
Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Saraçoğlu and colleagues at Marmara University in Istanbul, Turkey investigate
December 11, 2020 14:20
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to co
December 11, 2020 12:27
STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient in Phase 1b Trial of STP1
STALICLA SA, today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 sub
December 11, 2020 11:38
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug con
December 10, 2020 20:00
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual M
December 10, 2020 16:10
New Portal Allows Global Travellers to Book Mandatory Covid-19 Tests Around the World
Pure Health, the largest laboratory operator in the GCC, has launched a platform for travellers from any country to book Covid-19 pre-travel tests and get it done from anywhere in the world. The new p
December 10, 2020 15:55
Covetrus Completes Separation from Former Parent Company
Covetrus (Nasdaq: CVET), a global leader in animal-health technology and services, announced today that all 72 transitional services agreements with Henry Schein, Inc. (Nasdaq: HSIC), its former paren
December 10, 2020 10:57
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate i
December 08, 2020 16:59
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that China’s National Medical Products Administration (NMPA) has approved TAKHZYRO® (lanadelumab) subcutaneous inje
December 08, 2020 10:40
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic target
December 07, 2020 10:56
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin
December 07, 2020 10:49
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK
December 04, 2020 10:20
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery pla
December 02, 2020 17:05
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina®
December 02, 2020 16:56
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition
25 per page50 per page75 per page100 per page